MenACWY-CRM
Trials 27
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials · 1 met primary | ||||||
| Phase 2 | NCT01994629 | Nov 2013 → Apr 2014 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT01018732 | Jan → Jul 2010 | meningococcal meningitis | Novartis Vaccines | Completed | Met primary |
| Phase 2 | NCT00488683 | Jul 2007 → May 2009 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00560313 | Jul 2007 → Nov 2009 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00310856 | Jun 2005 → Nov 2006 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00262041 | Oct 2004 → Mar 2006 | meningococcemia | Novartis Vaccines | Completed | No outcome recorded |
| Phase 317 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT04440163 | Jun 2020 → Jul 2022 | meningococcal infection | Pfizer | Completed | Met primary |
| Phase 3 | NCT03135834 | Apr 2017 → Oct 2022 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01725217 | Nov 2012 → Mar 2013 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01410474 | Aug 2011 → Jan 2012 | bacterial meningitis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01345721 | May → Sep 2011 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01274897 | Dec 2010 → Mar 2011 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01214837 | Oct 2010 → Apr 2012 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01214850 | Sep 2010 → Jan 2012 | meningococcal infection | Novartis Vaccines | Completed | Missed primary |
| Phase 3 | NCT01148017 | Jul 2010 → Apr 2013 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01000311 | Nov 2009 → Nov 2011 | meningococcal infection | Novartis Vaccines | Completed | Met primary |
| Phase 3 | NCT00616421 | Mar 2008 → Apr 2009 | meningococcal infection | Novartis Vaccines | Completed | Mixed |
| Phase 3 | NCT00626327 | Feb 2008 → Jul 2010 | meningococcal infection | Novartis Vaccines | Completed | Met primary |
| Phase 3 | NCT00518180 | Jul 2007 → Apr 2008 | human papilloma virus infection, meningococcal meningitis, pertussis, tetanus | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00474487 | May → Aug 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00450437 | Mar → Aug 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00329849 | May 2006 → Mar 2007 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00329901 | Apr 2006 → May 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT03694405 | Sep 2018 → Aug 2021 | meningococcal infection | Canadian Immunization Research Network | Completed | No outcome recorded |
| Phase 4 | NCT01823536 | May → Oct 2013 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT01766206 | Mar 2013 → Jan 2018 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01424644 | Sep 2011 → Dec 2012 | meningococcal meningitis | Novartis | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT01272180 Comparator | Aug → Oct 2011 | meningococcal infection | Novartis Vaccines | Completed | Met primary |
| Phase 3 | NCT03691610 Comparator | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03077438 Comparator | Feb → Oct 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT01682876 Comparator | Oct 2012 → Jul 2013 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01453348 Comparator | Oct 2011 → Jan 2012 | hepatitis A virus infection, hepatitis B virus infection, meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT01593514 Comparator | Dec 2012 → Apr 2013 | bacterial infectious disease with sepsis, meningitis, meningococcal infection | University of Oxford | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-27 | GlaxoSmithKline | GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission gsk.com ↗ |
| 2024-09-24 | GlaxoSmithKline | GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion gsk.com ↗ |
| 2022-10-17 | GlaxoSmithKline | US FDA approves Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W gsk.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACWY CRM | “This was the first study of laboratory workers who received both a conjugate vaccine against meningococcal serogroups A, C, W-135, and Y (Men ACWY-CRM, Menveo) and an...” PMID 21177912 ↗ Dec 201033“MenACWY-CRM (Menveo®, Novartis Vaccines, Siena, Italy) is a quadrivalent meningococcal conjugate vaccine developed to help prevent invasive meningococcal disease caused by...” PMID 25075804 ↗ Jul 2014 “This study compares the safety and immunogenicity of the Novartis Vaccines investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, with the licensed...” PMID 19476428 ↗ Jul 2009 “This study compared the investigational quadrivalent meningococcal CRM₁₉₇ conjugate vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate...” PMID 20655261 ↗ Jul 2010 “This phase III study assessed the immunogenicity and safety of MenACYW-TT in children compared with a licensed quadrivalent meningococcal vaccine conjugated with diphtheria...” PMID 32852352 ↗ Oct 2020 “Infants were randomized 1:1 to receive MenACYW-TT (Group 1) or another quadrivalent conjugate vaccine, MenACWY-CRM (Group 2) at ages 6-7 and 12-13 months, co-administered with...” PMID 41792337 ↗ Mar 2026 “participants 10-25 years of age received 1 booster dose of MenABCWY vaccine at 24 months (M) postprimary series of MenABCWY (2 doses), 4CMenB (2 doses) or MenACWY-CRM vaccine (1 dose).” PMID 29329168 ↗ May 2018 “The quadrivalent meningococcal conjugate vaccine MenACWY-CRM has been shown to be immunogenic and well-tolerated in infants and toddlers.” PMID 31279564 ↗ Jul 2019 “Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)” NCT00329849 ↗ “MenACWY-CRM (≥7-≤10 years of age)” NCT01823536 ↗ “MenACWY-CRM (Novartis Vaccines)” PMID 20189491 ↗ Feb 2010 |
| Known as | MenACWY-CRM197 | “A quadrivalent meningococcal vaccine conjugated to CRM197 (MenACWY-CRM197) is immunogenic in young infants.” PMID 23566945 ↗ Apr 2013 |
| Known as | Meningococcal ACWY conjugate vaccine | “Biological: Meningococcal ACWY conjugate vaccine (MenACWY-CRM)” NCT00329901 ↗ |
| Known as | Menveo | “This was the first study of laboratory workers who received both a conjugate vaccine against meningococcal serogroups A, C, W-135, and Y (Men ACWY-CRM, Menveo) and an...” PMID 21177912 ↗ Dec 20103“MenACWY-CRM (Menveo®, Novartis Vaccines, Siena, Italy) is a quadrivalent meningococcal conjugate vaccine developed to help prevent invasive meningococcal disease caused by...” PMID 25075804 ↗ Jul 2014 “The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the...” NCT01593514 ↗ “MenACWY-CRM (Menveo)” NCT01766206 ↗ |
| Known as | Novartis MenACWY-CRM | “Novartis MenACWY-CRM” NCT01274897 ↗ |
| Known as | Novartis Meningococcal ACWY Conjugate Vaccine | “A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents...” NCT01725217 ↗1“Novartis Meningococcal ACWY Conjugate Vaccine” NCT01274897 ↗ |
| Modality | Vaccine | “Meningococcal ACWY Conjugate Vaccine” NCT00262041 ↗ |
| Route | Intramuscular | “administered by IM injection into the anterolateral area of the right thigh” NCT00310856 ↗ |